Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Synchrony Financial — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.4 (market cap $4.59B), while Synchrony Financial trades at $72.87 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 5.2× Definium Therapeutics Inc. Common Shares's market cap, and Synchrony Financial pays a 1.84% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Synchrony Financial for 28 Days on average.
| DFTX | SYF | |
|---|---|---|
Market Cap | $4.59B | $23.99B |
Volume | 2,103,937 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $48.45 | $88.47 |
52-Week Low | $10.68 | $63.78 |
Typical Hold Time | 0 Days | 28 Days |
Enterprise Value | $3.55B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synchrony Financial (SYF) trades at $73.16, up 1.71% on the day, with a bullish technical signal despite some bearish moving averages. The stock shows strong fundamentals, with a low P/E of 7.56 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten expectations, and the company is expanding through partnerships like the recent tie-up with Vetspire and OpenAI.
The outlook is positive, supported by analyst consensus with a $87.58 price target and 61% buy ratings. Key opportunities include high receivables growth and strategic AI integrations, while risks involve increased investing cash outflows and potential consumer credit stress amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
